Ovid Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ovid Therapeutics Inc. on June 27, 2019. The filing serves as a Regulation FD disclosure to announce the posting of a corporate presentation dated June 27, 2019, on the company's investor relations website.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation and does not contain audited financial statements or quarterly results.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary event is the public release of a corporate presentation regarding the company's business and clinical pipeline.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements contained in the attached corporate presentation (Exhibit 99.1). These statements cover:
- Progress, timing, and scope of clinical trials for product candidates.
- Reporting of clinical data and potential clinical benefits.
- Timing and outcomes of discussions with regulatory authorities.
- Success of potential partnering opportunities.
- Use of 24HC as a biomarker for target engagement.
The company notes that these forward-looking statements involve risks and uncertainties.
Key Facts for Investor Verification
- Verify the content of the corporate presentation attached as Exhibit 99.1 for specific clinical trial timelines and data.
- Confirm the company's status as an emerging growth company.
- Review the company's website (www.ovidrx.com) under the "Events & Presentations" section for the full disclosure.
- Note that the information in this 8-K is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.